6-(4-(4-fluorophenoxy)phenyl)-N-(2-(piperidin-1-yl)ethyl)picolinamide | 361437-01-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-(4-(4-fluorophenoxy)phenyl)-N-(2-(piperidin-1-yl)ethyl)picolinamide
• 英文别名: 6-[4-(4-fluorophenoxy)phenyl]pyridine carboxylic acid N-piperidinylethylamide；6-[4-(4-Fluorophenoxy)phenyl]-N-[2-(1-piperidinyl)ethyl]-2-pyridinecarboxamide；6-[4-(4-fluorophenoxy)phenyl]-N-(2-piperidin-1-ylethyl)pyridine-2-carboxamide
• CAS: 361437-01-6
• 化学式: C₂₅H₂₆FN₃O₂
• 分子量: 419.499
• InChiKey: AOMWTDFUWKTRKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  6-溴-2-吡啶羧酸 在 bis(triphenylphosphine)palladium(0) 、 potassium carbonate 、 1-羟基苯并三唑 、 达卡巴嗪 作用下， 以 乙二醇二甲醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 6-(4-(4-fluorophenoxy)phenyl)-N-(2-(piperidin-1-yl)ethyl)picolinamide
  参考文献：
  名称：

  苯氧苯基吡啶是新型的状态依赖性，高效钠通道抑制剂。

  摘要：

  为了寻找更有效的治疗神经性疼痛状态的药物，基于4-（4-氟苯氧基）苯甲醛半卡巴zone设计了一系列苯氧苯基吡啶。通过改变吡啶环上的取代基，鉴定了几种有效的状态依赖性钠通道抑制剂。从这些化合物中，在神经性疼痛的Chung模型中，有23种剂量依赖性逆转了触觉异常性疼痛。口服10 mg / kg的逆转水平约为。50％，相当于以100 mg / kg口服卡马西平的效果。

  DOI：

  10.1021/jm040048d

文献信息

• [EN] DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS<br/>[FR] INHIBITEURS DOUBLES DE NAV1.2/5HT2A POUR TRAITER DES TROUBLES DU SNC
  申请人：SUNOVION PHARMACEUTICALS INC

  公开号：WO2018026371A1

  公开（公告）日：2018-02-08

  Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

  公开了化学式I的化合物，以及含有这些化合物的药物组合物。还公开了治疗患有神经系统或精神障碍的患者的方法。这些障碍包括抑郁症、躁郁症、疼痛、精神分裂症、强迫症、成瘾、社交障碍、注意力缺陷多动障碍、焦虑障碍、自闭症、认知障碍，或神经精神症状，如冷漠、抑郁、焦虑、精神病、攻击性、激动、冲动控制障碍，以及在神经系统疾病如阿尔茨海默病和帕金森病中的睡眠障碍。
• Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof
  申请人：——

  公开号：US20020040025A1

  公开（公告）日：2002-04-04

  This invention relates aryl substituted pyridines, pyrimidines, pyrazines and triazines of Formula I: 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein A 1 , A 2 , A 3 , R 1 -R 4 , X and Y are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.

  该发明涉及式I的芳基取代吡啶、嘧啶、吡嗪和三嗪，或其药用可接受的盐、前药或溶剂化合物，其中A1、A2、A3、R1-R4、X和Y在规范中设定。该发明还涉及利用式I的化合物治疗全球性和局部性缺血后的神经损伤，治疗或预防神经退行性疾病，如肌萎缩性侧索硬化（ALS），以及治疗、预防或改善急性或慢性疼痛，作为抗耳鸣剂，抗抽搐剂，抗躁郁症药物，局部麻醉剂，抗心律失常药物，以及治疗或预防糖尿病性神经病变。
• Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US11186564B2

  公开（公告）日：2021-11-30

  Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

  式 I 的化合物： 以及含有此类化合物的药物组合物。还公开了治疗有需要的患者的神经或精神障碍的方法。此类疾病包括抑郁症、双相情感障碍、疼痛、精神分裂症、强迫症、成瘾症、社交障碍、注意力缺陷多动障碍、焦虑症、自闭症、认知障碍或神经精神症状，如冷漠、抑郁、焦虑、精神病、攻击性、激动、冲动控制障碍，以及神经系统疾病如阿尔茨海默病和帕金森病的睡眠障碍。
• ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF
  申请人：Euro-Celtique S.A.

  公开号：EP1265866A2

  公开（公告）日：2002-12-18
• DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US20190194163A1

  公开（公告）日：2019-06-27

  Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.